Shots:

• VALBIOTIS to receive ~$5.1M up front- ~$67.7 as development & commercial milestones and royalties on sales of therapy. Nestle to get exclusive global rights to commercialize TOTUM-63 in the prediabetes and T2D market
• The companies will jointly deal with clinical development- regulatory matters- supply and commercialization of the therapy. Additionally- VALBIOTIS will supply TOTUM-63 to Nestle representing an extra source of revenue
• TOTUM-63 is a patented combination of 5 plant extracts- designed to reduce the risk of developing T2D on prediabetics and demonstrated reduction in fasting and 2hrs. blood sugar levels in its P-II study

Click here ­to­ read full press release/ article | Ref: Buisnesswire | Image:  Nestle Health